Evidence map›Paper›PMID 41465422›Full record

ReviewInternational journal of molecular sciences2025

Glial Cells in the Early Stages of Neurodegeneration: Pathogenesis and Therapeutic Targets.

Eugenia Ahremenko, Alexander Andreev, Danila Apushkin, Eduard Korkotian

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Glial Cells in Behavioral and Psychological Symptoms of Alzheimer's Disease.International journal of molecular sciences · 2026
    Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Eugenia AhremenkoFaculty of Chemistry, Perm State University, 614068 Perm, Russia.ORCID 0000-0003-0757-064X
Alexander AndreevFaculty of Chemistry, Perm State University, 614068 Perm, Russia.
Danila ApushkinFaculty of Chemistry, Perm State University, 614068 Perm, Russia.ORCID 0000-0003-4459-5264
Eduard KorkotianFaculty of Chemistry, Perm State University, 614068 Perm, Russia.ORCID 0000-0001-5515-3387

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Astrocytes and microglia constitute nearly half of all central nervous system cells and are indispensable for its proper function. Both exhibit striking morphological and functional heterogeneity, adopting either neuroprotective (A2, M2) or proinflammatory (A1, M1) phenotypes in response to cytokines, pathogen-associated molecular patterns (PAMPs)/damage-associated molecular patterns (DAMPs), toll-like receptor 4 (TLR4) activation, and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome signaling. Crucially, many of these phenotypic transitions arise during the earliest stages of neurodegeneration, when glial dysfunction precedes overt neuronal loss and may act as a primary driver of disease onset. This review critically examines glial-centered hypotheses of neurodegeneration, with emphasis on their roles in early disease phases: (i) microglial polarization from an M2 neuroprotective state to an M1 proinflammatory state; (ii) NLRP3 inflammasome assembly via P2X purinergic receptor 7 (P2X7R)-mediated K

Indexed as

Neurodegenerative DiseasesNeurogliaAnimalsAstrocytesHumansInflammasomesMicrogliaNLR Family, Pyrin Domain-Containing 3 ProteinSignal TransductionInflammasomesNLR Family, Pyrin Domain-Containing 3 Proteinbiogenesis pathwaysglial cellsmice modelsmicroglia polarizationmitochondrial dysfunctionneurodegenerationphagocytosisphenotypestherapeutic targets

Identifiers

PMID41465422
PMCPMC12732986

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.